MK-0524: all 24 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)TerminatedNCT01414166Phase 3Results posted
- Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With DyslipoproteinemiaTerminatedNCT01239992Phase 4Results posted
- A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)CompletedNCT01012219Phase 1Results posted
- A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)CompletedNCT00769132Phase 1Results posted
- A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)CompletedNCT00618995Phase 1Results posted
- Effect of MK0524A on Cholesterol Levels (0524A-048)CompletedNCT00536510Phase 3Results posted
- Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)CompletedNCT00479388Phase 3Results posted
- Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVECompletedNCT00461630Phase 3Results posted
- Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin TreatmentCompletedNCT02153879Phase 4
- ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cARTTerminatedNCT01683656Phase 4
- A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)CompletedNCT01451619Phase 1
- Effects of Niacin on Good Cholesterol in People With Peripheral Arterial DiseaseTerminatedNCT01391377Not applicable
- Effect of Niacin in the Lipoprotein (a) ConcentrationCompletedNCT01321034Phase 4
- Niacin/Laropiprant and Endothelial FunctionCompletedNCT01126073Phase 4
- Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary SyndromeCompletedNCT01118598Phase 4
- Effect of Tredaptive on Serum Lipoproteins and Inflammatory MarkersCompletedNCT01054508Phase 4
- The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac PatientsTerminatedNCT01052311Phase 4
- Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed HyperlipidemiaStatus unknownNCT01010516Phase 4
- MK0524 Asthma POC Study (0524-008)(COMPLETED)CompletedNCT00783601Phase 2
- Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)WithdrawnNCT00664287Phase 3
- MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)CompletedNCT00533208Phase 2
- Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)CompletedNCT00378833Phase 3
- Lipid Efficacy/Tolerability Study (0524A-020)CompletedNCT00269204Phase 3
- An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)CompletedNCT00111891Phase 2